[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sinomed Neurovita Technology Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100606059","efficacy-and-safety-of-a-new-balloon-microcatheter-in-the-treatment-of-intracranial-artery-stenosis-100606059",false,"NCT07170618","Efficacy and Safety of a New Balloon Microcatheter in the Treatment of Intracranial Artery Stenosis","A Prospective, Multicenter, Objective Performance Criteria Study to Evaluate the Efficacy and Safety of a Balloon Microcatheter for Clinical Use","Inclusion Criteria:\n\n1. 18 to 80 years of age\n2. Patients with intracranial artery stenosis (Degree of stenosis: ≥70%)\n3. Target vessel reference diameter must be visually estimated to be 1.25 mm to 4.50 mm\n4. Willingness to participate in this clinical trial and signing the consent form for patients or their legally authorised representatives\n\nExclusion Criteria:\n\n1. The proximal end of the target vessel is extremely tortuous, severely angulated, or heavily calcified, making it difficult for the device to reach the target vessel\n2. Pre-existing severe respiratory, hepatic, or renal diseases (e.g., creatinine ≥ 3.0 mg\u002FdL) or coagulation disorders\n3. Disabling stroke with a baseline mRS score ≥ 3 points\n4. Non-atherosclerosis diseases\n5. Patients with stroke caused by branch occlusion\n6. Patients who were participating in other clinical trials who had not yet reached the primary clinical endpoint\n7. Known hypersensitivity to aspirin, heparin, anesthetics and contrast agents\n8. Investigators consider the patient who is not suitable for enrolling in the present trial","ALL","18 Years","80 Years",{"count":20,"type":21},56,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objective of this trial is to evaluate the safety and efficacy of a new balloon microcatheter in patients with intracranial artery stenosis.",[27],"Intracranial Artery Stenosis","NOT_YET_RECRUITING","2025-09-04",{"date":31,"type":32},"2025-09-12","ACTUAL",{"date":34,"type":21},"2025-09-01",{"date":36,"type":21},"2025-12-30",{"name":38,"class":39},"Sinomed Neurovita Technology Inc.","INDUSTRY",""]